Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (NasdaqGS:BLUE) from Underweight to Neutral. As of February 19, 2025, the average one-year price target for ...

Tevogen Bio Holdings Inc., a clinical-stage biotech firm specializing in immunotherapy, discussed its advancements in artificial intelligence (AI) during the J.P. Morgan Healthcare Conference. The ...

On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents. The gene therapy company ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, ...

Fintel reports that on November 7, 2025, JP Morgan maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Overweight ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve made it to the end of the week! Let’s keep it short and ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best stocks to buy with over 50% upside potential. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q3 2025 results on October 27 ...

J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs and build value for existing portfolio ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's ...

Thermo Fisher Scientific and Sony are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors.